Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After The Patent Cliff, "New" Sanofi Will Deliver Steady, Modest, Growth

Executive Summary

Sanofi is through the worst of its patent cliff and can deliver sales growth of at least 5% per year, on average, between 2012 and 2015, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts. And if 5% is a far cry from the double-digit pharma growth of yesteryear, investors may take heart from higher earnings growth, thanks in large part to an additional €2 billion ($2.8 billion) worth of cost savings and pared down R&D spend – and the promise of a higher dividend.

You may also be interested in...



Life Without Plavix: Sanofi Highlights Next Generation Drugs

Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.

Sanofi Targets 18 Drug Launches From 2012 To 2015

Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.

Sanofi Targets 18 Drug Launches From 2012 To 2015

Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.

Related Content

Topics

UsernamePublicRestriction

Register

PS053750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel